Comparable Study of Different Radiation Dose in Esophageal Carcinoma
Conditions
Esophageal Carcinoma
Conditions: official terms
Carcinoma - Esophageal Neoplasms
Conditions: Keywords
Esophageal Carcinoma, chemoradiation, radiation dose
Study Type
Interventional
Study Phase
Phase 3
Study Design
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Intervention
Name: intensity modulated radiation therapy in both arms Type: Radiation
Name: concurrent chemotherapy with radiation Type: Drug
Overall Status
Recruiting
Summary
Radiation therapy plus concurrent chemotherapy is now the standard therapy for patients with localized carcinoma of the esophagus selected for nonsurgical treatment. The standard radiation dose is 50-50.4Gy/1.8-2.0Gy/F.All of this were based on 2D radiation technology. Entering new century, 3D-CRT or IMRT has used on esophageal cancer. In China,the recommend radiation dose of concurrent chemoradiation was 60Gy. The study is a clinical phase III, randomized trial to compare the different radiation dose(60Gy vs 50Gy) of concurrent chemoradiation using 3D-CRT or IMRT in patients with unresectable esophageal carcinoma.
Criteria for eligibility
Healthy Volunteers: No
Maximum Age: 70 Years
Minimum Age: 18 Years
Gender: Both
Criteria: Inclusion Criteria:

- Histological or cytologic diagnosis of esophageal carcinoma

- ECOG performance status 0-1

- Age:18-70 years

- Joined the study voluntarily and signed informed consent form

- Patients must not have received any prior anticancer therapy

- Unresectable disease, or refuse surgery.Stage Ⅰ-ⅣA(AJCC 2009)

- Target lesions can be measured according to RECIST criteria

- No serious system dysfunction and immuno-deficiency, Adequate organ function including the following: Hemoglobin ≥9 g/dL, WBC≥3x109/L, Neutrophils (ANC )≥1.5x109/L, platelet count ≥100x 109/L, TBIL<1.5 x ULN, ALT and AST ≦ 2.5 x ULN, creatinine ≦ 1.5 x ULN

- Use of an effective contraceptive for adults to prevent pregnancy

- Life expectancy of more than 3 months

Exclusion Criteria:

- Multiple carcinomas of the esophagus,

- Biopsy-proven invasion of the tracheobronchial tree or tracheoesophageal fistula,

- Metastatic disease (M1),

- A primary tumor that extended to within 2 cm of the gastroesophageal junction,

- Prior chemotherapy, prior thoracic radiation, surgical resection of the primary tumor,

- Concurrent pregnancy or lactation, history of a second malignancy other than nonmelanoma skin cancer
Location
Zhejiang Cancer Hospital
Hangzhou, Zhejiang, China
Status: Recruiting
Contact: xiao zheng, MD - 0086-571-88122078 - zhengxiao@medmail.com
Start Date
August 2013
Completion Date
July 2017
Sponsors
Zhejiang Cancer Hospital
Source
Zhejiang Cancer Hospital
Record processing date
ClinicalTrials.gov processed this data on July 28, 2015
ClinicalTrials.gov page